Biosimilars Blog
What next for biosimilars? Five key questions…
The week, Duncan answers 5 key questions on the biosimilars market and what that holds for the future of biosimilars
Keep the faith, the most amazing things in life tend to happen right at the moment you’re about to give up hope…
Here I analyse and critique recent comments from Peter Bach and Mark Trusheim (MIT Sloan) on the U.S Biosimilar Market
The role of biosimilars in supporting the sustainable delivery of healthcare today and in the future
"Biosimilars are must-have weaponry in financially sustaining healthcare systems on a global scale as well as significantly improving outcomes for an increasing number of patients throughout Europe and the rest of the world.”
Key recent events from the European and US biosimilars market
This
blog will cover key recent events from the European and US biosimilars market,
including: insulin generics in the US, pegfilgrastim biosimilar launches in the
UK and Canada, and a new dosage form for a trastuzumab biosimilar in Europe
Will teenage years see the biosimilars market reach new heights, or will its growing pains continue?
Within this Biosimilars market anaysis we review the adoption of Biosimilars across the globe